<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 03 Apr 2025 02:55:11 +0000</lastbuilddate>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Incidence, risk factors, and mortality of pulmonary embolism in the Netherlands (2015-22): sex differences and shifts during the coronavirus disease 2019 pandemic</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40172984/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The seemingly favourable pre-pandemic temporal trends in PE epidemiology in the Netherlands reversed during the COVID-19 pandemic but appear to revert to pre-pandemic levels after 2022.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf211. doi: 10.1093/eurheartj/ehaf211. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Epidemiology of pulmonary embolism (PE) may have shifted since the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to describe temporal trends in PE epidemiology in the Netherlands since 2015.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using nationwide data from Statistics Netherlands, all Dutch inhabitants (>;16 million) without a history of PE were dynamically identified on 1 January of each year to assemble eight cohorts of PE-free Dutch inhabitants in 2015-22. They were individually followed until the end of that respective year to determine 1-year risk of PE (identified by hospital diagnoses/primary cause of death) and establish relevant risk factors. The PE cases were subsequently studied to determine 1-year all-cause mortality following PE. Multivariable logistic regression with cluster-robust standard errors and robust Poisson regression were respectively employed to evaluate relative differences in PE incidence and mortality between years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Pulmonary embolism incidence in the Dutch population decreased from 2015 to 2019 but markedly increased by 23% (95% confidence interval 20%-26%), 52% (48%-56%), and 7% (4%-9%) in 2020-22 (vs. 2019), respectively. Most traditional PE risk factors remained associated with PE in 2020-22 but generally with a weaker association. Pulmonary embolism mortality was stable until 2019 but then increased by 10% (6%-14%) in 2020 and 9% (6%-13%) in 2021, while the increase [2% (-1% to 6%)] was insignificant in 2022. The above-mentioned changes since 2020 were generally greater in males than females.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The seemingly favourable pre-pandemic temporal trends in PE epidemiology in the Netherlands reversed during the COVID-19 pandemic but appear to revert to pre-pandemic levels after 2022.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40172984/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40172984</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf211>10.1093/eurheartj/ehaf211</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40172984</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Qingui Chen</dc:creator>
<dc:creator>Nienke van Rein</dc:creator>
<dc:creator>Luuk J J Scheres</dc:creator>
<dc:creator>Eva K Kempers</dc:creator>
<dc:creator>Chantal Visser</dc:creator>
<dc:creator>Marieke J H A Kruip</dc:creator>
<dc:creator>Suzanne C Cannegieter</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Incidence, risk factors, and mortality of pulmonary embolism in the Netherlands (2015-22): sex differences and shifts during the coronavirus disease 2019 pandemic</dc:title>
<dc:identifier>pmid:40172984</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf211</dc:identifier>
</item>
<item>
<title>Comparing cardiology curricula: Europe vs. USA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40172953/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf105. doi: 10.1093/eurheartj/ehaf105. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40172953/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40172953</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf105>10.1093/eurheartj/ehaf105</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40172953</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Justin Brilliant</dc:creator>
<dc:creator>Floran Sahiti</dc:creator>
<dc:creator>Christine Mages</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Comparing cardiology curricula: Europe vs. USA</dc:title>
<dc:identifier>pmid:40172953</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf105</dc:identifier>
</item>
<item>
<title>Accountable Care Organization Participation and Cardiovascular Care Quality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40172907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Participation in an MSSP ACO was not found to be associated with early improvement in quality measures at outpatient cardiology practices.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Apr 2. doi: 10.1001/jamacardio.2025.0381. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The Medicare Shared Savings Program (MSSP) was introduced in 2012 to improve care quality and lower costs to Medicare. Under this program, accountable care organizations (ACOs) assumed responsibility for costs and care quality for a group of Medicare beneficiaries.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To compare changes in quality measures for patients at outpatient cardiology practices before and after their participation in a Medicare Shared Savings Program ACO.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This pre-post cohort study comparing quality prior to and after ACO participation evaluated the MSSP at 83 ACO outpatient cardiology practices compared with 332 non-ACO-participating cardiology practices, adjusted for secular trends, using 15 performance measures in the National Cardiovascular Data Registry PINNACLE (Practice Innovation and Clinical Excellence) Registry from January 1, 2013, through March 31, 2019. Data analysis was performed from 2022 to 2025.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Outpatient cardiology practice participation in the MSSP, which allows ACOs to share in the savings if predetermined cost targets are met, with payments adjusted based on a quality performance score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Primary end points included 15 quality measures for coronary artery disease, heart failure, atrial fibrillation, and hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During the study period, 2 390 244 patients (1 273 615 [53.3%] female; mean [SD] age, 58.5 [17.7] years) were cared for by 83 ACO practices, and 5 415 880 patients (2 810 204 [51.9%] female; mean [SD] age, 61.5 [16.3] years) were cared for by 332 non-ACO practices. Outpatient cardiology practice participation in an MSSP ACO was not associated with differential changes in various performance measures for coronary artery disease, heart failure, atrial fibrillation, and hypertension. There were no differential changes in the odds of β-blocker prescription, blood pressure control, antiplatelet prescription, angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) prescription, low-density lipoprotein (LDL) profiles, or smoking cessation for coronary artery disease; left ventricular assessment, β-blocker prescription, ACEI or ARB prescription, or implantable cardioverter defibrillator use for heart failure; anticoagulation for atrial fibrillation; or blood pressure control for hypertension. Exploratory analyses extending follow-up to 24 months revealed an increase in β-blocker use for heart failure (adjusted odds ratio [aOR], 1.23; 95% CI, 1.02-1.49; P = .03) and a decline in LDL profiles less than 100 mg/dL (to convert to millimoles per liter, multiply by 0.0259; aOR, 0.71; 95% CI, 0.51-0.999; P = .049). Among a subset of traditional Medicare patients, there was an increase in implantable cardioverter defibrillator use by 12 months (aOR, 1.66; 95% CI, 1.12-2.45; P = .01) following ACO participation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Participation in an MSSP ACO was not found to be associated with early improvement in quality measures at outpatient cardiology practices.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40172907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40172907</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0381>10.1001/jamacardio.2025.0381</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40172907</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Erica S Spatz</dc:creator>
<dc:creator>D August Oddleifson</dc:creator>
<dc:creator>Jehanzeb Kayani</dc:creator>
<dc:creator>Kensey L Gosch</dc:creator>
<dc:creator>Philip G Jones</dc:creator>
<dc:creator>Rushabh H Doshi</dc:creator>
<dc:creator>Thomas M Maddox</dc:creator>
<dc:creator>Nihar R Desai</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Accountable Care Organization Participation and Cardiovascular Care Quality</dc:title>
<dc:identifier>pmid:40172907</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0381</dc:identifier>
</item>
<item>
<title>Adverse Pregnancy Outcomes and N-Terminal Pro-Brain Natriuretic Peptide Levels 2 to 7 Years After Delivery: The nuMoM2b Heart Health Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40172904/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Apr 2. doi: 10.1001/jamacardio.2025.0325. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40172904/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40172904</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0325>10.1001/jamacardio.2025.0325</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40172904</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Priya M Freaney</dc:creator>
<dc:creator>Xiaoning Huang</dc:creator>
<dc:creator>Lucia C Petito</dc:creator>
<dc:creator>William A Grobman</dc:creator>
<dc:creator>Janet Catov</dc:creator>
<dc:creator>Alisse Hauspurg</dc:creator>
<dc:creator>C Noel Bairey Merz</dc:creator>
<dc:creator>Natalie Bello</dc:creator>
<dc:creator>Jin Kyung Kim</dc:creator>
<dc:creator>Abbi Lane</dc:creator>
<dc:creator>David M Haas</dc:creator>
<dc:creator>Lisa D Levine</dc:creator>
<dc:creator>Rebecca B McNeil</dc:creator>
<dc:creator>Eliza Miller</dc:creator>
<dc:creator>George Saade</dc:creator>
<dc:creator>Lauren Theilen</dc:creator>
<dc:creator>Lynn M Yee</dc:creator>
<dc:creator>Jasmina Varagic</dc:creator>
<dc:creator>Brian Mercer</dc:creator>
<dc:creator>Uma Reddy</dc:creator>
<dc:creator>Donald M Lloyd-Jones</dc:creator>
<dc:creator>Philip Greenland</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>National Heart, Lung, and Blood Institute nuMoM2b Heart Health Study Network</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Adverse Pregnancy Outcomes and N-Terminal Pro-Brain Natriuretic Peptide Levels 2 to 7 Years After Delivery: The nuMoM2b Heart Health Study</dc:title>
<dc:identifier>pmid:40172904</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0325</dc:identifier>
</item>
<item>
<title>Hypertensive Disorders of Pregnancy and Long-Term Risk of Dilated Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40172877/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Patients with hypertensive disorders of pregnancy had a greater risk of developing dilated cardiomyopathy. Older maternal age and postpartum hypertension were associated with higher risk of dilated cardiomyopathy after a hypertensive disorder of pregnancy. These findings support long-term clinical vigilance of patients with a history of hypertensive disorders of pregnancy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Apr 2. doi: 10.1001/jamacardio.2025.0328. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The impact of hypertensive disorders of pregnancy on developing dilated cardiomyopathy is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine whether hypertensive disorders of pregnancy are associated with long-term risk of dilated cardiomyopathy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study performed in England used the following linked electronic health records databases: Clinical Practice Research Datalink (CPRD) Pregnancy Register, CPRD Aurum (primary care), Hospital Episode Statistics Admitted Patient Care, and Office for National Statistics mortality data. Participants included an exposed cohort of 14 083 patients in their first pregnancy with hypertensive disorders of pregnancy (index date observed: January 1997 to December 2018; followed up until July 2023) and unexposed cohort of 70 415 with normotensive pregnancies randomly sampled from the Pregnancy Register (5:1 ratio).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Hypertensive disorder of pregnancy (preeclampsia, gestational hypertension).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Cox proportional hazards models were fitted to estimate hazard ratios (HRs) of developing dilated cardiomyopathy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The cohort included 14 083 individuals with a hypertensive disease of pregnancy during their first pregnancy and 70 415 individuals with normotensive first pregnancies. A first-time pregnancy complicated by a hypertensive disorder of pregnancy, compared with a normotensive first-time pregnancy, was associated with a 93% higher risk of developing dilated cardiomyopathy (adjusted HR, 1.93 [95% CI, 1.33-2.81]; P = .001; adjusted for maternal age). Dilated cardiomyopathy developed a median (IQR) of 5.1 (0.7-10.6) years post partum in those with HDP and 10.6 (4.2-15.8) years post partum in those with normotensive first pregnancies. The association remained significant after adjusting for maternal age, birth year, gestational diabetes, postpregnancy diabetes, postpregnancy hypertension, total parity, ethnicity, and socioeconomic status (adjusted HR, 1.55 [95% CI, 1.04-2.31]; P = .03). There was a dose response; there was a higher risk of DCM in those with preeclampsia (adjusted HR, 1.85 [95% CI, 1.24-2.76]; P = .002) and severe preeclampsia (adjusted HR, 4.29 [95% CI, 2.32-7.96]; P &lt; .001). Maternal age (adjusted HR per year of age, 1.06 [95% CI, 1.03-1.08]; P &lt; .001) and postpartum incident hypertension (adjusted HR, 1.68 [95% CI, 1.16-2.42]; P = .006) were independently associated with the development of DCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with hypertensive disorders of pregnancy had a greater risk of developing dilated cardiomyopathy. Older maternal age and postpartum hypertension were associated with higher risk of dilated cardiomyopathy after a hypertensive disorder of pregnancy. These findings support long-term clinical vigilance of patients with a history of hypertensive disorders of pregnancy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40172877/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40172877</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0328>10.1001/jamacardio.2025.0328</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40172877</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Upasana Tayal</dc:creator>
<dc:creator>Constantinos Kallis</dc:creator>
<dc:creator>Georgie M Massen</dc:creator>
<dc:creator>Nora Rossberg</dc:creator>
<dc:creator>Emily L Graul</dc:creator>
<dc:creator>Jennifer K Quint</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Hypertensive Disorders of Pregnancy and Long-Term Risk of Dilated Cardiomyopathy</dc:title>
<dc:identifier>pmid:40172877</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0328</dc:identifier>
</item>
<item>
<title>Grading valve regurgitation by AI is solved: What's next?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40172299/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf257. doi: 10.1093/eurheartj/ehaf257. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40172299/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40172299</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf257>10.1093/eurheartj/ehaf257</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40172299</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Neal Yuan</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Grading valve regurgitation by AI is solved: What's next?</dc:title>
<dc:identifier>pmid:40172299</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf257</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40172094/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Feb 28;136(5):453-454. doi: 10.1161/RES.0000000000000710. Epub 2025 Feb 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40172094/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40172094</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000710>10.1161/RES.0000000000000710</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40172094</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:date>2025-04-02</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:40172094</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000710</dc:identifier>
</item>
<item>
<title>Transcatheter vs. surgical aortic valve replacement in women: the RHEIA trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171878/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among women with severe aortic stenosis, the incidence of the composite of death, stroke, or rehospitalization at 1 year was lower with TAVI than with surgery.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf133. doi: 10.1093/eurheartj/ehaf133. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Although women with severe symptomatic aortic stenosis have more complications than men when undergoing surgical valve replacement, they are under-represented in clinical trials. The Randomized researcH in womEn all comers wIth Aortic stenosis (RHEIA) trial investigates the balance of benefits and risks of transcatheter aortic valve implantation (TAVI) vs. surgery in women.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Women were randomized 1:1 to transfemoral TAVI with a balloon-expandable valve or surgery. The primary composite endpoint was death, stroke, or (valve, procedure or heart failure related) rehospitalization at 1 year. Non-inferiority testing with a pre-specified 6% margin and superiority testing were performed in the as-treated population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At 48 European centres, 443 women underwent randomization, and 420 were treated as randomized. Mean age was 73 years, and the mean estimated surgical risk of death was 2.1% (Society of Thoracic Surgeons risk score). Kaplan-Meier estimates of the primary endpoint event rates at 1 year were 8.9% in the TAVI and 15.6% in the surgery group. This difference of -6.8% with an upper 95% confidence limit of -1.5% demonstrated the non-inferiority of TAVI (P &lt; .001). The two-sided 95% confidence interval of -13.0% to -.5% further resulted in superiority (P = .034). The 1-year incidence of the primary endpoint components was: .9% with TAVI vs. 2.0% with surgery for death from any cause, 3.3% vs. 3.0% for stroke, and 5.8% vs. 11.4% for rehospitalization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among women with severe aortic stenosis, the incidence of the composite of death, stroke, or rehospitalization at 1 year was lower with TAVI than with surgery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS.GOV NUMBER: NCT04160130.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171878/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40171878</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf133>10.1093/eurheartj/ehaf133</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171878</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Didier Tchetche</dc:creator>
<dc:creator>Philippe Pibarot</dc:creator>
<dc:creator>Jeroen J Bax</dc:creator>
<dc:creator>Nikolaos Bonaros</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Nicolas Dumonteil</dc:creator>
<dc:creator>Fabian Nietlispach</dc:creator>
<dc:creator>David Messika-Zeitoun</dc:creator>
<dc:creator>Stuart J Pocock</dc:creator>
<dc:creator>Pierre Berthoumieu</dc:creator>
<dc:creator>Martin J Swaans</dc:creator>
<dc:creator>Leo Timmers</dc:creator>
<dc:creator>Tanja Katharina Rudolph</dc:creator>
<dc:creator>Sabine Bleiziffer</dc:creator>
<dc:creator>Lionel Leroux</dc:creator>
<dc:creator>Thomas Modine</dc:creator>
<dc:creator>Frank van der Kley</dc:creator>
<dc:creator>Vincent Auffret</dc:creator>
<dc:creator>Jacques Tomasi</dc:creator>
<dc:creator>Lukas Stastny</dc:creator>
<dc:creator>Christian Hengstenberg</dc:creator>
<dc:creator>Martin Andreas</dc:creator>
<dc:creator>Florence Leclercq</dc:creator>
<dc:creator>Thomas Gandet</dc:creator>
<dc:creator>Julia Mascherbauer</dc:creator>
<dc:creator>Karola Trescher</dc:creator>
<dc:creator>Bernard Prendergast</dc:creator>
<dc:creator>Mariuca Vasa-Nicotera</dc:creator>
<dc:creator>Alaide Chieffo</dc:creator>
<dc:creator>Jan Mares</dc:creator>
<dc:creator>Wilbert Wesselink</dc:creator>
<dc:creator>Radka Rakova</dc:creator>
<dc:creator>Jana Kurucova</dc:creator>
<dc:creator>Peter Bramlage</dc:creator>
<dc:creator>Helene Eltchaninoff</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transcatheter vs. surgical aortic valve replacement in women: the RHEIA trial</dc:title>
<dc:identifier>pmid:40171878</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf133</dc:identifier>
</item>
<item>
<title>The Year in Cardiovascular Medicine 2024: the top 10 papers in interventional cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171771/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf106. doi: 10.1093/eurheartj/ehaf106. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171771/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40171771</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf106>10.1093/eurheartj/ehaf106</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171771</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Emanuele Barbato</dc:creator>
<dc:creator>Tommaso Gori</dc:creator>
<dc:creator>Margaret McEntegart</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The Year in Cardiovascular Medicine 2024: the top 10 papers in interventional cardiology</dc:title>
<dc:identifier>pmid:40171771</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf106</dc:identifier>
</item>
<item>
<title>EMA601 and glenzocimab: two glycoprotein VI inhibitory Fabs with different potency</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171679/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf162. doi: 10.1093/eurheartj/ehaf162. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171679/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40171679</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf162>10.1093/eurheartj/ehaf162</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171679</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Bernhard Nieswandt</dc:creator>
<dc:creator>David Stegner</dc:creator>
<dc:creator>Stefano Navarro</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>EMA601 and glenzocimab: two glycoprotein VI inhibitory Fabs with different potency</dc:title>
<dc:identifier>pmid:40171679</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf162</dc:identifier>
</item>
<item>
<title>European Research Council-funded grant: the embryonic obesogenic environment and cardiovascular diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171678/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf141. doi: 10.1093/eurheartj/ehaf141. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171678/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40171678</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf141>10.1093/eurheartj/ehaf141</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171678</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Romy Gaillard</dc:creator>
<dc:creator>Vincent W V Jaddoe</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>European Research Council-funded grant: the embryonic obesogenic environment and cardiovascular diseases</dc:title>
<dc:identifier>pmid:40171678</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf141</dc:identifier>
</item>
<item>
<title>Leaders in cardiology: Molly Stevens</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171674/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf140. doi: 10.1093/eurheartj/ehaf140. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171674/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40171674</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf140>10.1093/eurheartj/ehaf140</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171674</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Leaders in cardiology: Molly Stevens</dc:title>
<dc:identifier>pmid:40171674</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf140</dc:identifier>
</item>
<item>
<title>European Research Council-funded grant: maintenance of platelet homeostasis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehae881. doi: 10.1093/eurheartj/ehae881. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40171672</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae881>10.1093/eurheartj/ehae881</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171672</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Dulce Papy-Garcia</dc:creator>
<dc:creator>Omer Dushek</dc:creator>
<dc:creator>Yotis A Senis</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>European Research Council-funded grant: maintenance of platelet homeostasis</dc:title>
<dc:identifier>pmid:40171672</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae881</dc:identifier>
</item>
<item>
<title>Critical medications in cardiology: strategic policy of the European Medicines Agency</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171671/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf134. doi: 10.1093/eurheartj/ehaf134. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171671/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40171671</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf134>10.1093/eurheartj/ehaf134</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171671</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Dobromir Dobrev</dc:creator>
<dc:creator>Juan Tamargo</dc:creator>
<dc:creator>Piotr Szymański</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Critical medications in cardiology: strategic policy of the European Medicines Agency</dc:title>
<dc:identifier>pmid:40171671</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf134</dc:identifier>
</item>
<item>
<title>Australia: challenges and opportunities for cardiologists</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171664/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf136. doi: 10.1093/eurheartj/ehaf136. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171664/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40171664</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf136>10.1093/eurheartj/ehaf136</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171664</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Australia: challenges and opportunities for cardiologists</dc:title>
<dc:identifier>pmid:40171664</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf136</dc:identifier>
</item>
<item>
<title>European Research Council-funded grant: long non-coding RNA in adipocytes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171663/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf129. doi: 10.1093/eurheartj/ehaf129. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171663/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40171663</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf129>10.1093/eurheartj/ehaf129</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171663</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Alastair G Kerr</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>European Research Council-funded grant: long non-coding RNA in adipocytes</dc:title>
<dc:identifier>pmid:40171663</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf129</dc:identifier>
</item>
<item>
<title>Glycoprotein VI inhibitors: glenzocimab and EMA601 two inhibitory Fabs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171661/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf160. doi: 10.1093/eurheartj/ehaf160. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171661/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40171661</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf160>10.1093/eurheartj/ehaf160</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171661</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Pierre H Mangin</dc:creator>
<dc:creator>Martine Jandrot-Perrus</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Glycoprotein VI inhibitors: glenzocimab and EMA601 two inhibitory Fabs</dc:title>
<dc:identifier>pmid:40171661</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf160</dc:identifier>
</item>
<item>
<title>PCSK9 Regulates Cardiac Mitochondrial Cholesterol by Promoting TSPO Degradation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171648/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings indicate that PCSK9 regulates mitochondrial cholesterol levels by modulating the TSPO degradation in the heart. Modulation of mitochondrial cholesterol by targeting TSPO may be a promising therapeutic approach for heart failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Apr 2. doi: 10.1161/CIRCRESAHA.124.325629. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cholesterol is critical for mitochondrial membrane structure and function. Given the emergence of mitochondria as a key factor in the pathogenesis of heart failure, mitochondrial cholesterol homeostasis may be crucial for maintaining mitochondrial properties and thus cardiac function. We previously showed that CM-<i>Pcsk9</i><sup>-/-</sup> mice (mice with cardiomyocyte-specific deletion of PCSK9 [proprotein convertase subtilisin-kexin type 9]) have impaired cardiomyocyte mitochondrial bioenergetics and heart function, paralleled by cardiomyocyte mitochondrial cholesterol accumulation and an increased number of mitochondria-endoplasmic reticulum contacts. However, the mechanisms linking PCSK9 to mitochondrial cholesterol homeostasis remain unclear. We hypothesized that PCSK9 acts on proteins involved in mitochondrial cholesterol trafficking in the heart to maintain cardiac mitochondrial function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: By performing RNA sequencing and immunoblot on CM-<i>Pcsk9</i><sup>-/-</sup> and CM-<i>Pcsk9</i><sup>+/+</sup> mouse hearts, we showed that TSPO (translocator protein) was increased by <i>Pcsk9</i> deficiency. To investigate the relationship between <i>TSPO</i> levels and heart function in humans, we compared the transcriptome of human left ventricles with high versus low <i>TSPO</i> levels. We used H9c2 (a rat cardiomyoblast cell line) cardiomyocytes to explore the mechanism linking PCSK9/TSPO to mitochondrial cholesterol content and function. The impact of reduced TSPO levels on cardiac function and mitochondrial oxidation in CM-<i>Pcsk9</i><sup>-/-</sup> mice was tested using adeno-associated virus serotype 9 short hairpin TSPO.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Both gene and protein levels of TSPO, a mitochondrial protein involved in cholesterol transport, were increased in CM-<i>Pcsk9</i><sup>-/-</sup> mouse hearts. Transcriptome analysis showed that high <i>TSPO</i> expression in human left ventricles was associated with impaired mitochondrial and cardiac function. We showed that PCSK9 induced TSPO degradation through a proteasomal mechanism that occurs in cardiomyocytes but not hepatocytes and contributes to maintaining normal mitochondrial cholesterol composition and function. At the molecular level, endoplasmic reticulum-resident PCSK9 interacted with GRP78, reducing GRP78-TSPO interactions and leading to TSPO misfolding and degradation by the ubiquitin-proteasome pathway. Importantly, gene therapy-induced downregulation of TSPO in CM-<i>Pcsk9</i><sup>-</sup><sup>/</sup><sup>-</sup> mice prevented mitochondrial cholesterol accumulation and improved cardiac function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings indicate that PCSK9 regulates mitochondrial cholesterol levels by modulating the TSPO degradation in the heart. Modulation of mitochondrial cholesterol by targeting TSPO may be a promising therapeutic approach for heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171648/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40171648</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325629>10.1161/CIRCRESAHA.124.325629</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171648</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Marion Laudette</dc:creator>
<dc:creator>Malin Lindbom</dc:creator>
<dc:creator>Mathieu Cinato</dc:creator>
<dc:creator>Per-Olof Bergh</dc:creator>
<dc:creator>Kristina Skålén</dc:creator>
<dc:creator>Arif Muhammad</dc:creator>
<dc:creator>Azra Miljanovic</dc:creator>
<dc:creator>Tomasz Czuba</dc:creator>
<dc:creator>Rosie Perkins</dc:creator>
<dc:creator>J Gustav Smith</dc:creator>
<dc:creator>Frank Lezoualc'h</dc:creator>
<dc:creator>Malin C Levin</dc:creator>
<dc:creator>Jan Borén</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>PCSK9 Regulates Cardiac Mitochondrial Cholesterol by Promoting TSPO Degradation</dc:title>
<dc:identifier>pmid:40171648</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325629</dc:identifier>
</item>
<item>
<title>Optimizing stem cell infusion timing in the prevention of acute graft-versus-host disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40168995/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a cornerstone treatment for a broad spectrum of malignant and nonmalignant hematological disorders. However, the success of allo-HSCT is often overshadowed by acute graft-versus-host disease (aGVHD), a life-threatening complication. Here, we show in patients and murine models that the circadian timing of stem cell infusion dictates the development of aGVHD. Early-infused patients exhibit a significantly lower incidence and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 27:S0092-8674(25)00295-8. doi: 10.1016/j.cell.2025.03.022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a cornerstone treatment for a broad spectrum of malignant and nonmalignant hematological disorders. However, the success of allo-HSCT is often overshadowed by acute graft-versus-host disease (aGVHD), a life-threatening complication. Here, we show in patients and murine models that the circadian timing of stem cell infusion dictates the development of aGVHD. Early-infused patients exhibit a significantly lower incidence and severity of aGVHD, as well as improved survival. We observed time-of-day variations in the levels of cytokines, especially IL-1α, which controls donor T cell responses after transplantation. The levels of IL-1α in patients were strongly associated with the development of aGVHD. Furthermore, preclinical results showed that the administration of IL-1α neutralizing antibodies markedly alleviated aGVHD and increased survival. Our study suggests that scheduling stem cell infusions early in the day could be a simple yet transformative intervention for preventing aGVHD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40168995/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40168995</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.03.022>10.1016/j.cell.2025.03.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40168995</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Yiwen Hou</dc:creator>
<dc:creator>Yue Wu</dc:creator>
<dc:creator>Yang Cao</dc:creator>
<dc:creator>Xiaoxia Hu</dc:creator>
<dc:creator>Yuqian Sun</dc:creator>
<dc:creator>Hongmei Wang</dc:creator>
<dc:creator>Liang Wang</dc:creator>
<dc:creator>Jialin Zhou</dc:creator>
<dc:creator>Zhonglin Zhang</dc:creator>
<dc:creator>Zhiwei Liu</dc:creator>
<dc:creator>Baolin Tang</dc:creator>
<dc:creator>Kaidi Song</dc:creator>
<dc:creator>Guangyu Sun</dc:creator>
<dc:creator>Wen Gao</dc:creator>
<dc:creator>Tianqi Zheng</dc:creator>
<dc:creator>Ping Wu</dc:creator>
<dc:creator>Weiwei Wu</dc:creator>
<dc:creator>Dapeng Ju</dc:creator>
<dc:creator>Xiaoyu Zhu</dc:creator>
<dc:creator>Cheng Zhan</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Optimizing stem cell infusion timing in the prevention of acute graft-versus-host disease</dc:title>
<dc:identifier>pmid:40168995</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.03.022</dc:identifier>
</item>
<item>
<title>Global analysis of protein turnover dynamics in single cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40168994/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>Single-cell proteomics (SCPs) has advanced significantly, yet it remains largely unidimensional, focusing primarily on protein abundances. In this study, we employed a pulsed stable isotope labeling by amino acids in cell culture (pSILAC) approach to simultaneously analyze protein abundance and turnover in single cells (SC-pSILAC). Using a state-of-the-art SCP workflow, we demonstrated that two SILAC labels are detectable from ∼4,000 proteins in single HeLa cells recapitulating known biology. We...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 26:S0092-8674(25)00275-2. doi: 10.1016/j.cell.2025.03.002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Single-cell proteomics (SCPs) has advanced significantly, yet it remains largely unidimensional, focusing primarily on protein abundances. In this study, we employed a pulsed stable isotope labeling by amino acids in cell culture (pSILAC) approach to simultaneously analyze protein abundance and turnover in single cells (SC-pSILAC). Using a state-of-the-art SCP workflow, we demonstrated that two SILAC labels are detectable from ∼4,000 proteins in single HeLa cells recapitulating known biology. We performed a large-scale time-series SC-pSILAC analysis of undirected differentiation of human induced pluripotent stem cells (iPSCs) encompassing 6 sampling times over 2 months and analyzed >;1,000 cells. Protein turnover dynamics highlighted differentiation-specific co-regulation of protein complexes with core histone turnover, discriminating dividing and non-dividing cells. Lastly, correlating cell diameter with the abundance of individual proteins showed that histones and some cell-cycle proteins do not scale with cell size. The SC-pSILAC method provides a multidimensional view of protein dynamics in single-cell biology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40168994/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40168994</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.03.002>10.1016/j.cell.2025.03.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40168994</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Pierre Sabatier</dc:creator>
<dc:creator>Maico Lechner</dc:creator>
<dc:creator>Ulises H Guzmán</dc:creator>
<dc:creator>Christian M Beusch</dc:creator>
<dc:creator>Xinlei Zeng</dc:creator>
<dc:creator>Longteng Wang</dc:creator>
<dc:creator>Fabiana Izaguirre</dc:creator>
<dc:creator>Anjali Seth</dc:creator>
<dc:creator>Olga Gritsenko</dc:creator>
<dc:creator>Sergey Rodin</dc:creator>
<dc:creator>Karl-Henrik Grinnemo</dc:creator>
<dc:creator>Zilu Ye</dc:creator>
<dc:creator>Jesper V Olsen</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Global analysis of protein turnover dynamics in single cells</dc:title>
<dc:identifier>pmid:40168994</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.03.002</dc:identifier>
</item>
<item>
<title>Mechanism of DNA capture by the MukBEF SMC complex and its inhibition by a viral DNA mimic</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40168993/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250402225511&amp;v=2.18.0.post9+e462414
      <description>Ring-like structural maintenance of chromosome (SMC) complexes are crucial for genome organization and operate through mechanisms of DNA entrapment and loop extrusion. Here, we explore the DNA loading process of the bacterial SMC complex MukBEF. Using cryoelectron microscopy (cryo-EM), we demonstrate that ATP binding opens one of MukBEF's three potential DNA entry gates, exposing a DNA capture site that positions DNA at the open neck gate. We discover that the gp5.9 protein of bacteriophage T7...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 27:S0092-8674(25)00259-4. doi: 10.1016/j.cell.2025.02.032. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ring-like structural maintenance of chromosome (SMC) complexes are crucial for genome organization and operate through mechanisms of DNA entrapment and loop extrusion. Here, we explore the DNA loading process of the bacterial SMC complex MukBEF. Using cryoelectron microscopy (cryo-EM), we demonstrate that ATP binding opens one of MukBEF's three potential DNA entry gates, exposing a DNA capture site that positions DNA at the open neck gate. We discover that the gp5.9 protein of bacteriophage T7 blocks this capture site by DNA mimicry, thereby preventing DNA loading and inactivating MukBEF. We propose a comprehensive and unidirectional loading mechanism in which DNA is first captured at the complex's periphery and then ingested through the DNA entry gate, powered by a single cycle of ATP hydrolysis. These findings illuminate a fundamental aspect of how ubiquitous DNA organizers are primed for genome maintenance and demonstrate how this process can be disrupted by viruses.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40168993/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250402225511&v=2.18.0.post9+e462414">40168993</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.032>10.1016/j.cell.2025.02.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40168993</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Frank Bürmann</dc:creator>
<dc:creator>Bryony Clifton</dc:creator>
<dc:creator>Sophie Koekemoer</dc:creator>
<dc:creator>Oliver J Wilkinson</dc:creator>
<dc:creator>Dari Kimanius</dc:creator>
<dc:creator>Mark S Dillingham</dc:creator>
<dc:creator>Jan Löwe</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Mechanism of DNA capture by the MukBEF SMC complex and its inhibition by a viral DNA mimic</dc:title>
<dc:identifier>pmid:40168993</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.032</dc:identifier>
</item>





























</channel>
</rss>